Fig. 4.

Synergistic effects of mT16A#5 and Cetuximab on the inhibition of ESCC metastasis and growth. A, B Combination of mT16A#5 and Cetuximab inhibited migration and invasion of KYSE30lm3 cells. A Transwell chamber assays. B Matrigel invasion assays. C–E mT16A#5 and Cetuximab have synergistic effect on inhibiting footpad metastasis of ESCC in mice. C KYSE30lm3 cells were injected subcutaneously into the footpad of the right hindfoot of mice, and whole-body imaging was performed on each group of mice after four weeks of consecutive treatment to observe the metastasis of the footpad tumor. D Statistical graph of fluorescence intensity of each mouse foot. E Statistical graph of body weight of mice in each group at the end of treatment. F–H The mT16A#5 and Cetuximab had a synergistic effect on the inhibition of subcutaneous ESCC tumor growth in mice. F KYSE30lm3 cells were injected into the subcutaneous part of the right coeliac region of mice. The mice were executed after four weeks of treatment, and the tumors were stripped and observed for growth. G Statistical graph of subcutaneous tumor mass of mice in each group at the end of treatment. H Statistical graph of body weight of mice in each group at the end of treatment *P < 0.05, **P < 0.01, ***P < 0.001, ns P > 0.05